Search

Displaying results 2371 - 2380 of 7604 in total
  1. Drug

    Voxilaprevir

    go.drugbank.com/drugs/DB12026
    ApprovedInvestigational

    Voxilaprevir is a Direct-Acting Antiviral (DAA) medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV) … Prior to Vosevi, there were no approved retreatment options for patients who have previously received, and failed, a regimen containing an NS5A inhibitor for treatment of chronic HCV infection.

  2. Drug

    Enfortumab vedotin

    go.drugbank.com/drugs/DB13007
    ApprovedInvestigational

    [L10836] Enfortumab vedotin was later approved by the European Commission on April 13, 2022.[L42000] … [L10836] It is comprised of a fully human monoclonal antibody targeted against Nectin-4 and a microtubule-disrupting chemotherapeutic agent, monomethyl auristatin E (MMAE), joined by a protease-cleavable

  3. Drug

    Besilesomab

    go.drugbank.com/drugs/DB13979
    Approved

    Utilised only as a diagnostic agent, besilesomab is currently approved by the EMEA for marketing and use in various European countries like Italy, France, Germany, Spain, Portugal, Norway, Sweden, the

  4. Drug

    Enoxacin

    go.drugbank.com/drugs/DB00467
    Approved

    A broad-spectrum 6-fluoronaphthyridinone antibacterial agent (fluoroquinolones) structurally related to nalidixic acid.

  5. Drug

    Dermatophagoides farinae

    go.drugbank.com/drugs/DB10400
    ApprovedInvestigational

    Dermatophagoides farinae extracts are sterile solutions used for intradermal testing or subcutaneous immunotherapy. This combination is approved for as a year-round, once-a-day tablet that's dissolved under the tongue as a treatment for ...

  6. Drug

    Dermatophagoides pteronyssinus

    go.drugbank.com/drugs/DB10401
    ApprovedInvestigational

    Dermatophagoides pteronyssinus extracts are sterile solutions used for intradermal testing or subcutaneous immunotherapy. This combination is approved for as a year-round, once-a-day tablet that's dissolved under the tongue as a treatmen...

  7. Drug

    Peginterferon alfa-2b

    go.drugbank.com/drugs/DB00022
    ApprovedInvestigational

    Peginterferon alfa-2b is derived from the alfa-2b moeity of recombinant human interferon and acts by binding to human type 1 interferon receptors. … Peginterferon alfa-2b is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV).

  8. Drug

    Ethotoin

    go.drugbank.com/drugs/DB00754
    Approved

    Ethotoin is no longer commonly used. … The latter drug appears to stabilize rather than to raise the normal seizure threshold, and to prevent the spread of seizure activity rather than to abolish the primary focus of seizure discharges.

  9. Drug

    Temoporfin

    go.drugbank.com/drugs/DB11630
    Approved

    It was first authorized for market by the European Medicines Agency in October 2001. It is currently available under the brand name Foscan.

  10. Drug

    Candoxatril

    go.drugbank.com/drugs/DB00616
    Experimental

    Candoxatril is the orally-active prodrug of candoxatrilat (UK-73967), a potent neutral endopeptidase (NEP) inhibitor.